| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 14224 | 2012 |
| Final version of 2009 AJCC melanoma staging and classification CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ... Journal of clinical oncology 27 (36), 6199-6206, 2009 | 5655 | 2009 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ... Journal of Clinical Oncology 36 (17), 1714-1768, 2018 | 3741 | 2018 |
| Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma CM Balch, AC Buzaid, SJ Soong, MB Atkins, N Cascinelli, DG Coit, ... Journal of Clinical Oncology 19 (16), 3635-3648, 2001 | 3348 | 2001 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 3086 | 2019 |
| Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system CM Balch, SJ Soong, JE Gershenwald, JF Thompson, DS Reintgen, ... Journal of clinical oncology 19 (16), 3622-3634, 2001 | 2995 | 2001 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020-1030, 2014 | 2743 | 2014 |
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 MB Atkins, MT Lotze, JP Dutcher, RI Fisher, G Weiss, K Margolin, ... Journal of clinical oncology 17 (7), 2105-2105, 1999 | 2538 | 1999 |
| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2409 | 2019 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2365 | 2009 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2350 | 2017 |
| Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ... CA: a cancer journal for clinicians 67 (6), 472-492, 2017 | 2271 | 2017 |
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy GT Gibney, LM Weiner, MB Atkins The Lancet Oncology 17 (12), e542-e551, 2016 | 1657 | 2016 |
| Combined nivolumab and ipilimumab in melanoma metastatic to the brain HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ... New England Journal of Medicine 379 (8), 722-730, 2018 | 1274 | 2018 |
| Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ... Journal of clinical oncology 22 (5), 909-918, 2004 | 1190 | 2004 |
| Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 H Tilg, E Trehu, MB Atkins, CA Dinarello, JW Mier | 1186 | 1994 |
| Management of cutaneous melanoma H Tsao, MB Atkins, AJ Sober New England Journal of Medicine 351 (10), 998-1012, 2004 | 1132 | 2004 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of Clinical Oncology 39 (36), 4073-4126, 2021 | 1130 | 2021 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1109 | 2018 |
| Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production JP Leonard, ML Sherman, GL Fisher, LJ Buchanan, G Larsen, MB Atkins, ... Blood, The Journal of the American Society of Hematology 90 (7), 2541-2548, 1997 | 1095 | 1997 |
